Hawryluk Matthew
Known title: DirectorCIK: 0001754470
Associated companies
Transaction History
| AGPU | ▲ Buy | Grant | 733 | $0 | 10/1/2026 | View on chart |
| AGPU | ▲ Buy | Grant | 1,716 | $0 | 7/1/2026 | View on chart |
| AGPU | ▲ Buy | Grant | 6,782 | $0 | 4/20/2026 | View on chart |
| AGPU | ▲ Buy | Grant | 64,680 | $0 | 9/9/2025 | View on chart |
| AGPU | ▲ Buy | Grant | 2,368 | $0 | 4/5/2024 | View on chart |
| AGPU | ▲ Buy | Grant | 1,875 | $0 | 10/2/2023 | View on chart |
| AGPU | ▲ Buy | Grant | 2,675 | $0 | 7/3/2023 | View on chart |
| AGPU | ▲ Buy | Grant | 18,360 | $0 | 4/3/2023 | View on chart |
| AGPU | ▲ Buy | Grant | 19,570 | $0 | 1/3/2023 | View on chart |
| AGPU | ▲ Buy | Grant | 13,762 | $0 | 12/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Axe Compute Signs $266M in AI Contracts, Exits Cancer Business
Axe Compute has secured over $266 million in new AI infrastructure contracts since mid-August. The company is also selling its cancer business to fully transition into an AI-focused entity. These moves mark a significant strategic shift for the stock, which trades with high beta and has a wide 52-week range.
Axe Compute Signs $266M in AI Contracts, Exits Cancer Business. Axe Compute has secured over $266 million in new AI infrastructure contracts since mid-August. The company is also selling its cancer business to fully transition into an AI-focused entity. These moves mark a significant strategic shift for the stock, which trades with high beta and has a wide 52-week range.